Newsroom
What we’re building,and where it is running.
Company news, partnerships and compliance milestones from CellAuto and the National Engineering Center for the Cell Industry. A selection of recent stories, translated into English.
Latest news
Recent stories.
The most recent company news and milestones. For the full archive, including industry commentary, see the Chinese site.
CellAuto Drives Biomanufacturing Upgrade Through Production-Line Transformation
How CellAuto breaks the national advanced-manufacturing strategy into three routes, intelligent cell lines, autonomous radiopharmaceutical equipment and virology laboratory automation, all built on the fusion of BT, AT and IT.
Read more →Under Lecheng’s New Rules, How Can Cell Projects Localise On Time and Stay Compliant?
Lecheng’s draft rules make on-time localised preparation, traceable quality control and continuous data reporting hard obligations. CellAuto’s automated line and digital QC make meeting them practical and reproducible.
Read more →Officially Certified: Beike Biotechnology Passes Lecheng’s First Laboratory Compliance Inspection
Beike Biotechnology (Qionghai) passed Lecheng’s first on-site laboratory compliance inspection running CellAuto’s fully-automated cell manufacturing platform, which was recognised as GMP-compliant.
Read more →Sterility, Quality Management and Radiation Safety: CellAuto’s “Three Swords” of Nuclear-Medicine Automation
One integrated answer to the three regulatory dimensions of radiopharmaceutical manufacturing, benchmarked against EU GMP Annex 1, the EU GMP framework and USP <825>.
Read more →Indonesian Stem-Cell Delegation Visits the National Engineering Center for the Cell Industry
A delegation led by Dr Lestari Poediastoeti Indah explored joint stem-cell research and the possibility of a regional cell-manufacturing centre in Indonesia, adding momentum to Belt and Road biomedical cooperation.
Read more →CellAuto’s AI Cell-Monitoring Platform: A Pioneering Model for “AI + Drug Regulation”
A non-invasive platform that segments bright-field cell images and predicts quality attributes such as IDO1 expression, an early response to China’s “AI + Drug Regulation” strategy.
Read more →CellAuto Safeguards China’s First Approved Stem-Cell Clinical Application for Type-2 Diabetes
CellAuto provided the fully-automated, compliant manufacturing behind China’s first approved umbilical-cord mesenchymal stem-cell therapy for Type-2 diabetes, launched in Boao Lecheng.
Read more →Fujian CDMO Platform of the National Engineering Center for the Cell Industry Launches
The Center’s Fujian branch and an intelligent automated cell-drug CDMO translation platform launched at the Fujian Maternity and Child Health Hospital, opening a compliant clinical-translation pathway.
Read more →Want to covera CellAuto story?
For press enquiries, interviews or more detail on any of these projects, get in touch and our team will respond.